Return to Common Drugs Index
nizatidine
Axid, Axid AR, Tazac‡

Pregnancy Risk Category C

How supplied
Tablets:
75 mg
Capsules:
150 mg, 300 mg

Action
Competitively inhibits action of H2 at receptor sites of the parietal cells, decreasing gastric acid secretion.

Indications & dosage
Active duodenal ulcer--

Adults:
300 mg P.O. daily h.s. Or, 150 mg P.O. b.i.d.
Maintenance therapy for duodenal
ulcer--

Adults:
150 mg P.O. daily h.s.
Benign gastric ulcer
--
Adults:
150 mg P.O. b.i.d. or 300 mg h.s. for 8 weeks.
Gastroesophageal reflux disease (GERD)--

Adults:
150 mg P.O. b.i.d. for up to 12 weeks.
Adjust-a-dose:
For renally impaired patients with creatinine clearance of 20 to 50 ml/minute, 150 mg P.O. daily for treatment of active duodenal ulcer, benign gastric ulcer, or GERD; or 150 mg every other day for maintenance therapy. If creatinine clearance is below 20 ml/minute, 150 mg P.O. every other day for treatment, or 150 mg every third day for maintenance.

Adverse reactions
CNS:
somnolence.
CV:
arrhythmias.
Hematologic:
eosinophilia.
Hepatic:
elevated liver function tests results, hepatocellular injury.
Metabolic:
hyperuricemia.
Skin:
diaphoresis, rash, urticaria.
Other:
fever.

Interactions
Drug-drug.
Aspirin: possibly elevated serum salicylate levels (with high doses). Monitor closely.
Drug-food.
Tomato-based vegetable juices: may decrease potency of drug when used concomitantly. Don't use together.

Effects on diagnostic tests
False-positive test results for urobilinogen may occur during drug therapy.

Contraindications
Contraindicated in patients with hypersensitivity to H2-receptor antagonists.

Nursing considerations

Patient teaching

*Liquid contains alcohol. **May contain tartrazine.  †Canada  ‡Australia  §U.K.  OTCOver the counter
Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING

Return to Common Drugs Index